January 11, 2021 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced the publication of a peer-reviewed study to evaluate outcomes from using midline catheters for blood collection in the Journal of the Association for Vascular Access.
The primary purpose of this study was to evaluate the processes, uses and outcomes of using the BD PowerGlide Pro Midline Catheters for the purpose of blood collection for laboratory analysis.
Findings indicated that blood withdrawal from the BD PowerGlide Pro Midline Catheter had low rates of hemolysis, increased dwell time (the length of time the catheter remains in the body) and completion of therapy. According to the company, this option may reduce need for direct venipuncture in patients who have midline catheters with ongoing or frequent blood collection for testing, which may reduce the number of venipunctures for patients during their hospital stay. Fewer needlesticks can reduce complications and lead to greater patient satisfaction, BD said.
The PowerGlide Pro Midline Catheter is inserted into a patient’s vascular system for short-term use (<30 days) to sample blood or administer fluids intravenously. These catheters may be useful for any patient population with consideration given to adequacy of vascular anatomy and appropriateness of the procedure. The PowerGlide Pro Midline Catheter is suitable for use with power injectors.